WESTMINSTER, Colo., May 19 /PRNewswire-FirstCall/ -- Stockholders of Allos
Therapeutics, Inc. (Nasdaq: ALTH), voting at the Company's 2005 Annual Meeting
of Stockholders held yesterday, May 18, 2005, approved the issuance of shares
of the Company's common stock upon exchange of shares of the Company's
Series A Exchangeable Preferred Stock sold to Warburg Pincus Private Equity
VIII, L.P. and certain other investors in a financing transaction in
March 2005. As a result of such approval, the Company issued a total of
23,524,430 shares of common stock upon exchange of 2,352,443 shares of
Series A Exchangeable Preferred Stock. After giving effect to the share
exchange, the Company now has approximately 54.7 million shares of common
stock outstanding, of which Warburg Pincus owns approximately 22.6 million
shares, or 41.4%.
The Company's stockholders also approved all other matters brought before
the meeting, including the election of directors and ratification of the
Company's independent auditors. A full tally of the votes will be published
in the Company's quarterly report on Form 10-Q, which will be filed with the
Securities and Exchange Commission on or about August 10, 2005.
About Allos Therapeutics, Inc.
Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company
focused on developing and commercializing innovative small molecule
therapeutics for the treatment of cancer. Our lead product candidate,
EFAPROXYN(TM) (efaproxiral), is a synthetic small molecule designed to
sensitize hypoxic, or oxygen-deprived, tumor tissue during radiation therapy.
EFAPROXYN is currently being evaluated as an adjunct to whole brain radiation
therapy in a pivotal Phase 3 trial in women with brain metastases originating
from breast cancer. Our other product candidates are: PDX (pralatrexate), a
small molecule chemotherapeutic agent (DHFR inhibitor) currently under
investigation as both a single agent and in combination therapy regimens in
patients with non-small cell lung cancer and Non-Hodgkin's lymphoma; and RH1,
a small molecule chemotherapeutic agent bioactivated by the enzyme
DT-diaphorase currently under evaluation in patients with advanced solid
tumors. For more information, visit the company's website at http://www.allos.com.
Note: EFAPROXYN(TM) and the Allos logo are trademarks of Allos
Therapeutics, Inc.
SOURCE Allos Therapeutics, Inc.
 back to top
Related links:
http://www.allos.com
CONTACT:
Jennifer Neiman, Manager, Corporate
Communications of Allos Therapeutics, +1-720-540-5227,
jneiman@allos.com
|
